文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

宫颈癌一次施源器中MRI引导两次自适应近距离放疗分次与一次自适应近距离放疗分次的比较:一项回顾性研究

The MRI-guided two adaptive brachytherapy fractions versus one adaptive brachytherapy fraction in one application for the cervical cancer: a retrospective study.
PubMed 文献 · Radiat Oncol · 2023-03-06

该回顾性研究比较宫颈癌一次施源器中MRI引导自适应近距离放疗(IGABT)两次分次与一次分次的临床与毒性结局,共120例患者,Arm 1为63例每次施源器一次IGABT,Arm 2为57例至少一次治疗为一次施源器隔日连续两次IGABT。结果显示Arm 2总治疗时间显著缩短(60 vs 64天,P=0.017),生存结局无显著差异,部分疼痛评分有显著差异,已报告4例3级晚期毒性。

要点

  • 一次施源器隔日连续两次IGABT较一次IGABT总治疗时间显著缩短(60 vs 64天,P=0.017)。
  • 两组OS、CSS、PFS、LC均无显著差异(P值分别为0.632、0.821、0.207、0.583)。
  • 等待期及取施源器时疼痛最高NRS在两组间有显著差异(P<0.001)。

核心结论

  • 作者认为一次施源器隔日连续两次IGABT是后勤可实施、安全且有效的治疗策略,与一次施源器一次IGABT相比可缩短总治疗时间并降低医疗费用。

研究设计与样本

  • 回顾性研究,纳入120例接受外照射放疗联合或不联合同步化疗后行IGABT的宫颈癌患者。
  • Arm 1为63例每次施源器一次IGABT,Arm 2为57例至少一次治疗为一次施源器隔日连续两次IGABT。
  • 采用Kaplan-Meier法和Log-rank检验分析临床结局,采用CTC-AE 5.0评估泌尿系统、下消化道及生殖系统毒性的发生率和严重程度。

主要发现

  • Arm 1与Arm 2中位随访时间分别为23.5个月和12.0个月。
  • Arm 2总治疗时间显著短于Arm 1(60 vs 64天;P=0.017)。
  • Arm 1 vs Arm 2的OS为77.8% vs 86.0%(P=0.632),CSS为77.8% vs 87.7%(P=0.821),PFS为68.3% vs 70.2%(P=0.207),LC为92.1% vs 94.7%(P=0.583),均无显著差异。
  • 接受一次施源器一次近距离放疗与一次施源器隔日连续两次近距离放疗的患者,等待期疼痛最高NRS为2.22±1.84 vs 3.02±1.65(P<0.001),取施源器时疼痛最高NRS为4.69±1.49 vs 5.30±1.18(P<0.001),差异有统计学意义。
  • 目前已报告4例3级晚期毒性患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study retrospectively compared the clinical and toxicity outcomes for the cervical cancer of the MRI-guided two adaptive brachytherapy (IGABT) fractions versus one IGABT fraction in one application. METHODS: One hundred and twenty patients with cervical cancer received external beam radiotherapy combined with or without concurrent chemotherapy, which was followed by the IGABT. The IGABT in 63 patients had one IGABT in each application (Arm 1), while in the other 57 patients, at least one treatment was two continuous IGABT every other day in one application (Arm 2). Clinical outcomes including overall survival (OS), cancer specific survival (CSS), progression free survival (PFS), local control (LC) were analyzed. Brachytherapy-related toxicities were evaluated, which included pain, dizziness, nausea/vomiting, fever/infection, blood loss during the removal of applicator and needles, the deep venous thrombosis, and other acute toxicities. The Common Terminology Criteria for Adverse Events (CTC-AE 5.0) was used to evaluate the incidence and severity of toxicities of the urinary system, lower digestive system, and reproduction system. Kaplan-Meier and the Log-rank test were used to analyze the clinical outcomes. RESULTS: The median follow-up time of the patients in Arm 1 and Arm 2 was 23.5 and 12.0 months, respectively. The overall treatment time was significantly shorter in Arm 2 than Arm 1 (60 vs. 64 d; P = 0.017). The OS, CSS, PFS, and LC in Arm1 and Arm 2 was 77.8% vs. 86.0% (P = 0.632), 77.8% vs. 87.7% (P = 0.821), 68.3% vs. 70.2% (P = 0.207), and 92.1% vs. 94.7% (P = 0.583), respectively. The highest NRS of the pain during brachytherapy waiting period (2.22 ± 1.84 vs. 3.02 ± 1.65; P < 0.001) and at the time of the removal of the applicator (4.69 ± 1.49 vs. 5.30 ± 1.18; P < 0.001) in the patients who received one hybrid intracavitary and interstitial brachytherapy (IC/ISBT) in one application and two continuous IC/ISBT every other day in one application were significantly different. So far four patients with grade 3 late toxicities have been reported. CONCLUSIONS: The findings of this study demonstrated that the two continuous IGABT every other day in one application is a logistically applicable, safe, and effective treatment strategy that could shorten the overall treatment time and reduce the medical cost, comparing with the one IGABT in one application.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Song S, Han D, Zhang N, et al. The MRI-guided two adaptive brachytherapy fractions versus one adaptive brachytherapy fraction in one application for the cervical cancer: a retrospective study. Radiat Oncol. 2023. PMID: 36879287. doi:10.1186/s13014-023-02237-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。